April 2022: British Achilles Therapeutics plc is a leading company in cancer evolution, bioinformatics and the development of cell-based immunotherapies.
It is using DNA sequencing data from each patient and a proprietary bioinformatics platform to identify clonal neo-antigens specific to that patient to enable the development of personalized cell therapies.
“We are pleased to expand our global presence with our first American lab facility in Center City. Our selected site with 50,000 sq suits well the scope of our U.S. R&D needs. This address is the critical life sciences hub in the Philadelphia region, joining other active life science companies.”
said Dr. Iraj Ali, CEO at Achilles Therapeutics.
More Posts
Weidmüller Group Bolsters U.S. Manufacturing with $16.4m Expansion in Virginia, adding over 100 jobs
